the grow. pressure large of record quarter our allowing or good ones to which Parag. by welcome. drivers us ROCE. through is strategy and risk uncertainties, and In multiple is business keeping environment you We well-diversified and market performance, sign of am economic the EBITDA and a take event. last to believe us inflationary here, to allows built that a or volatility the years, pleased sales, current current which and dependent the marked you, Thank growth morning, everyone. have Good we ForEx I on being geopolitical model, have are hope to few and evening reduce you I your
fluctuation taking will that investing our to enable be pipeline portfolio agenda. our and with may there innovation drive aspirations. along markets, a driving sustainable cash line position net across our in While ESG productivity, we us We with building some on for focus forward quarter-on-quarter, believe strategy, growth
some U.S. Russia of share the of normalization the partner, USFBpproval successful sales Let capsuled products. last went launch after by One current Pitestream of this of rebound stock you commercialization our limited highlights of our volume visibility improving market. in key in to quarter. of and me rechannel of Minalidumide commercialization quarter. received the
internally manufacturing referred FTI, facility for in Global largest call. Our joined a Hyderabad economic as Lighthouse network the
currencies. take section me business let highlights this numbers you the in note the the Please key respective quarter. Now through that references in current to all are local for
a North product limited largely Our growth launch of of attributed volume to Generics of the market. This basis. with for million XX% quarter, the contribution capsules sales strong including the $XXX lenalidomide in recorded year-over-year and the business America sequential was on new launch in the U.S. a XX%
quarters business we within mention quarter, While and last we over erosion balance expect able transcend value wouldn't continue of to during contribute in next these momentum X be -- has sales products to over been launched arising continue will few quarters The the from base moment volume we X products [indiscernible], meaningfully or the. as price specific the the the the for this expect us to well.
growth and growth sales with XX% Our a Europe year-to-year of recorded of million this X%. of quarter $XX sequential quarter business
XX During Europe. various products within new the we across launched quarter, countries
with FY the continue 'XX. momentum rest growth We expect in to the of
business with INRX,XXX market year-on-year sales of recorded decline crores a X%. of Our emerging
of Adjusted had was growth to this due a stocking 'XX. sales COVID market effect within segment, The as quarter-to-quarter sequential in the the we COVID QX sales Russia Russia for However, The business basis a currency. to quarter levels normalized have higher X%. we and FY contribution, product and year-over-year a year-to-endecline growth last reverted declined on on grown base for emerging XX% the basis in -- a after normal quarter. constant channel a by in inventory X% grew the by has of
we countries markets. of XX various across new During products emerging launched the quarter,
for We momentum continue expect B. in the this business to growth
for sequential in recorded Our of brand XX%. crores grown QX have FY India sales 'XX, the mid-teens mid-single of X% income of QX the a during year-over-year and year and 'XX, digits a covid FY and business product sequentially. growth divestment in we decline INRX,XXX Adjusted with
launched the X During products quarter, market. we a in new
is rank number June value terms XX. in per at our tube As report a of MAT XXXX,
We noncore portfolio to focus India brand business for acquisitions, growing partnerships in continue will brands. with focus big divesting while reset our of therapy,
million of by XX% sequential product over the of sales a and last in decline decline XX%. for volume year. recorded business $XX some The key FY COVID 'XX, of pickup single with of due QX been digits business declined the lower PCI Our over-year sales decline Adjusted in has the products. customers of has to for
up of with quarters over expect pick volume products. launch increasing sales We of and new next the couple improvement
journey of a been building and differentiated well and of have pipeline. We products, in complex progressing biosimilar our NC portfolio
our to also list have of made a a We progress to moves good branded markets. identify innovation
our committed with pursue actively to the current our opportunities businesses there like opportunities uncertain to that continue strategy. in believe strategy. open floor multiple I investment to in line look the answers. even our environment, and questions business, for We in for we With to with are would and this, line are for grow this We
